biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC

On Apr 25, 2016

biOasis Technologies has entered into a License Agreement to collaborate with Astellas Research Institute of America (Astellas).

The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and assessment of the biOasis Transcend technology.

biOasis CEO Rob Hutchison said: “We at biOasis are looking forward to working with Astellas’s US Research Institute in the pursuit of taking Transcend commercially forward.

“Over the coming months, biOasis and Astellas will work to outline specific programs and to commence the execution of them in a timely manner.”

biOasis Technologies is a biopharmaceutical company headquartered in Vancouver, Canada.

Based on Transcend, biOasis’ proprietary brain delivery platform, the Company is focused on enabling Pharmaceutical companies to deliver their brain-targeted therapeutics.